当前位置: X-MOL 学术Diabetes › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice
Diabetes ( IF 6.2 ) Pub Date : 2023-02-24 , DOI: 10.2337/db22-0784
Tianjiao Wei 1, 2 , Xiaona Cui 1, 2 , Yafei Jiang 1 , Kangli Wang 1 , Dandan Wang 1 , Fei Li 1 , Xiafang Lin 1 , Liangbiao Gu 1 , Kun Yang 1 , Jin Yang 1, 3 , Tianpei Hong 1, 3, 4 , Rui Wei 1, 3, 4
Affiliation  

Dysfunction of glucagon-secreting α-cells participates in the progression of diabetes, and glucagon receptor (GCGR) antagonism is regarded as a novel strategy for diabetes therapy. GCGR antagonism upregulates glucagon and glucagon-like peptide-1 (GLP-1) secretion, and notably promotes β-cell regeneration in diabetic mice. Here, we aimed to clarify the role of GLP-1 receptor (GLP-1R) activated by glucagon and/or GLP-1 in the GCGR antagonism-induced β-cell regeneration. We showed that in db/db mice and type 1 diabetic wild-type or Flox/cre mice, GCGR monoclonal antibody (mAb) improved glucose control, upregulated plasma insulin level, and increased β-cell area. Notably, blockage of systemic or pancreatic GLP-1R signaling by exendin 9-39 (Ex9) or Glp1r knockout diminished the above effects of GCGR mAb. Furthermore, glucagon neutralizing antibody (nAb), which prevents activation of GLP-1R by glucagon, also attenuated the GCGR mAb-induced insulinotropic effect and β-cell regeneration. In cultured primary mouse islets isolated from normal mice and db/db mice, GCGR mAb action to increase insulin release, and to upregulate β-cell specific marker expression, was reduced by a glucagon nAb, or by the GLP-1R antagonist Ex9, or by a pancreasspecific Glp1r knockout. These findings suggest that activation of GLP-1R by glucagon participates in β-cell regeneration induced by GCGR antagonism in diabetic mice.

中文翻译:

作用于 GLP-1 受体的胰高血糖素有助于糖尿病小鼠胰高血糖素受体拮抗作用诱导的 β 细胞再生

胰高血糖素分泌 α 细胞的功能障碍参与糖尿病的进展,胰高血糖素受体 (GCGR) 拮抗作用被认为是糖尿病治疗的新策略。GCGR 拮抗作用上调胰高血糖素和胰高血糖素样肽-1 (GLP-1) 的分泌,并显着促进糖尿病小鼠的 β 细胞再生。在这里,我们旨在阐明由胰高血糖素和/或 GLP-1 激活的 GLP-1 受体 (GLP-1R) 在 GCGR 拮抗作用诱导的 β 细胞再生中的作用。我们发现,在 db/db 小鼠和 1 型糖尿病野生型或 Flox/cre 小鼠中,GCGR 单克隆抗体 (mAb) 改善了葡萄糖控制,上调了血浆胰岛素水平,并增加了 β 细胞面积。值得注意的是,exendin 9-39 (Ex9) 或 Glp1r 敲除对全身或胰腺 GLP-1R 信号的阻断削弱了 GCGR mAb 的上述作用。此外,胰高血糖素中和抗体 (nAb) 可防止胰高血糖素激活 GLP-1R,还可减弱 GCGR mAb 诱导的促胰岛素作用和 β 细胞再生。在从正常小鼠和 db/db 小鼠分离的培养的原代小鼠胰岛中,GCGR mAb 增加胰岛素释放和上调 β 细胞特异性标记物表达的作用被胰高血糖素 nAb 或 GLP-1R 拮抗剂 Ex9 降低,或通过胰腺特异性 Glp1r 敲除。这些发现表明,胰高血糖素对 GLP-1R 的激活参与了糖尿病小鼠 GCGR 拮抗作用诱导的 β 细胞再生。并且为了上调 β 细胞特异性标记物的表达,胰高血糖素 nAb、GLP-1R 拮抗剂 Ex9 或胰腺特异性 Glp1r 基因敲除都会降低。这些发现表明,胰高血糖素对 GLP-1R 的激活参与了糖尿病小鼠 GCGR 拮抗作用诱导的 β 细胞再生。并且为了上调 β 细胞特异性标记物的表达,胰高血糖素 nAb、GLP-1R 拮抗剂 Ex9 或胰腺特异性 Glp1r 基因敲除都会降低。这些发现表明,胰高血糖素对 GLP-1R 的激活参与了糖尿病小鼠 GCGR 拮抗作用诱导的 β 细胞再生。
更新日期:2023-02-24
down
wechat
bug